Anavex Life Sciences Corp.
AVXL
$9.42
-$0.03-0.32%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 16.78% | 7.23% | -11.98% | -3.23% | -18.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.20% | 13.80% | 9.54% | -10.36% | -26.38% |
| Operating Income | -22.20% | -13.80% | -9.54% | 10.36% | 26.38% |
| Income Before Tax | -40.47% | -15.02% | -9.27% | 20.04% | 33.64% |
| Income Tax Expenses | -- | -93.75% | -263.41% | 110.00% | -- |
| Earnings from Continuing Operations | -40.47% | -14.53% | -8.28% | 19.54% | 33.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.47% | -14.53% | -8.28% | 19.54% | 33.53% |
| EBIT | -22.20% | -13.80% | -9.54% | 10.36% | 26.38% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -36.00% | -10.66% | -3.58% | 23.60% | 36.90% |
| Normalized Basic EPS | -35.92% | -10.67% | -4.95% | 18.45% | 36.89% |
| EPS Diluted | -36.00% | -10.66% | -3.58% | 23.60% | 36.90% |
| Normalized Diluted EPS | -35.92% | -10.67% | -4.95% | 18.45% | 36.89% |
| Average Basic Shares Outstanding | 3.32% | 3.44% | 4.53% | 5.31% | 5.26% |
| Average Diluted Shares Outstanding | 3.32% | 3.44% | 4.53% | 5.31% | 5.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |